Schweizer, A., Dejager, S., et al. (2011) Clinical Experience with Vidagliptin in the Management of Type 2 Diabetes in a Patient Population ≥75 Years: A Pooled Analysis from a Database of Clinical Trials. Diabetes, Obesity and Metabolism, 13, 55-64.
http://dx.doi.org/10.1111/j.1463-1326.2010.01325.x
-
TITLE:
Sitagliptin for Elderly Patients Aged 75 Years or Older with Inadequately Controlled Type 2 Diabetes with Common Antidiabetes Treatments
AUTHORS:
Katsunori Suzuki, Yurie Mistuma, Takaaki Sato, Mariko Hatta
KEYWORDS:
Elderly, Sitagliptin, Type 2 Diabetes Mellitus
JOURNAL NAME:
International Journal of Clinical Medicine,
Vol.6 No.9,
September
23,
2015
ABSTRACT: Background: The purpose of this study was to evaluate the effects of sitagliptin in elderly patients with type 2 diabetes aged 75 years or older versus those aged 65 - 74 years. Methods: Outpatients aged 65 years or older with type 2 diabetes who received sitagliptin at a dose of 50 mg daily for 6 months were divided into two groups: those who were 75 years and older and those who were 65 - 74 years. The efficacy and safety were retrospectively evaluated by comparison of laboratory values before and after the administration of sitagliptin and by review of adverse events after treatment. Results: One hundred and twelve older patients with type 2 diabetes were studied. Six months after the initiation of sitagliptin, participants’ hemoglobin A1c was significantly decreased by 1.09% ± 0.8% in 65 - 74-year-olds (66 patients; mean age, 69.1 ± 3.0 years; mean HbA1c before administration, 8.4% ± 0.8%) and by 1.05% ± 0.8% in patients 75 years or older (46 patients; mean age, 79.8 ± 4.1 years; mean HbA1c before administration, 8.5% ± 0.7%). There was no significant difference in hemoglobin A1c between the two groups. Furthermore, sitagliptin was well tolerated in both age groups. Conclusions: In elderly patients (75 years or older) with type 2 diabetes, the effect of sitagliptin was similar that in older patients (younger than 75 years) with type 2 diabetes.
Related Articles:
Cost-benefit analysis of screening for diabetic retinopathy among Chinese type 2 diabetes: decision from different perspectives of a population-based study
Ching-Ching Peng, Pesus Chou, Tao-Hsin Tung, Wu-Hsiung Chien, Fenq-Lih Lee, Shih-Jen Chen, Shih-Tzer Tsai, Chi-Ming Liu, Jorn-Hon Liu
DOI:
10.4236/health.2009.14050
5,282 Downloads 10,057 Views Citations
Pub. Date:
December
30,
2009
